Results 31 to 40 of about 171,176 (147)
Diagnostic Value of PVT for Severe Sleep Inertia in Idiopathic Hypersomnia. ABSTRACT Sleep inertia impairs performance upon awakening and may be assessed using the psychomotor vigilance task (PVT). This study aimed to determine optimal PVT lapse cut‐offs at awakening to objectively measure sleep inertia by comparing patients with idiopathic hypersomnia
Elisa Evangelista +6 more
wiley +1 more source
ABSTRACT Sleep supports memory consolidation. Non‐rapid eye movement (NREM) and rapid eye movement (REM) sleep have been proposed to support, respectively, declarative memory consolidation and the integration of the memory affective dimension. Here, we used sodium oxybate (SXB) to modify the NREM/REM proportion during one sleep night and assessed ...
Laure Colin +7 more
wiley +1 more source
Pathophysiological Models of Hypersomnolence Associated With Depression
Up to 25% of patients with depression experience hypersomnolence (e.g., excessive daytime sleepiness, hypersomnia, and/or sleep inertia), which is associated with treatment resistance, overall poorer outcomes, and safety concerns while driving ...
Christophe Moderie, Diane B. Boivin
doaj +1 more source
ABSTRACT Objective This study aimed to identify and characterize drugs associated with reports of head injury through a comprehensive analysis of the FDA Adverse Event Reporting System (FAERS) database. Methods A retrospective disproportionality analysis was conducted on FAERS reports from 2004 to 2023.
Jiaqi Guo +5 more
wiley +1 more source
Unveiling the Power of Deuterium in Drug Discovery: A Comprehensive Overview
The role of deuterium replacement in drug discovery, its progress, opportunities, and challenges. ABSTRACT Deuterium, the heavy isotope of hydrogen, has unfolded as a cornerstone in modern drug discovery due to its potential to influence metabolic stability and pharmacokinetic behavior.
Mukta Lele +7 more
wiley +1 more source
article, ‘Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study,’
Yves Dauvilliers +4 more
openaire +2 more sources
Towards Mechanism‐Informed Treatments for Mental Health
Neuropsychiatric disorders impose a major global health burden, and current treatments, which historically mostly targeted dopamine and serotonin dysfunctions, often provide only partial, symptomatic relief. This review highlights emerging evidence that additional neuromodulator systems, including acetylcholine, norepinephrine, and endocannabinoids ...
Iker Bengoetxea de Tena +27 more
wiley +1 more source
Implication of the thalamus in sleep alterations observed in Alzheimer's disease
Abstract Alzheimer's disease (AD), the most common neurodegenerative disorder, is frequently accompanied by sleep disturbances. Alterations of sleep, in both quality and quantity, contribute to the progression of AD neuropathology. The thalamus, through its diverse nuclei, plays a central role in sleep regulation and sleep‐dependent memory ...
Carla Burnet‐Merlin +2 more
wiley +1 more source
Treatment approaches in posthypoxic myoclonus: A narrative review with expert opinion
Abstract Acute posthypoxic myoclonus (PHM) is a neurological complication that typically emerges within 12–48 h following cardiac arrest, often in comatose patients. It can present as generalized, multifocal, or focal myoclonus and has traditionally been associated with poor prognosis.
Marina Romozzi +7 more
wiley +1 more source
Abstract Background and aims Gamma‐hydroxybutyrate (GHB) is an endogenous neurochemical and illicit synthetic drug. Its precursors, gamma‐butyrolactone (GBL) and 1,4‐butanediol (1,4‐BD), are often used as substitutes. We aimed to describe GHB‐related harms in New South Wales (NSW), Australia.
Krista J. Siefried +9 more
wiley +1 more source

